Zobrazeno 1 - 10
of 18
pro vyhledávání: '"M Violet, Lee"'
Autor:
Gail D. Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T. Fields, Genee Lee, Donglu Zhang, Peter S. Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M. Violet Lee, Ola Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Hamilton, Patricia LoRusso, Ian Krop, Melissa M. Schutten, Renee Commerford, Mark X. Sliwkowski, Eunpi Cho
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzuma
Externí odkaz:
https://doaj.org/article/654b41b090ea4a87be21fb42ec554dae
Autor:
M. Violet Lee, Ola M. Saad, Sylvia Wong, Jason LaMar, Lynn Kamen, Ben Ordonia, Rachel Melendez, Azadeh Hassanzadeh, Shan Chung, Surinder Kaur
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Major histocompatibility complex (MHC)-Associated Peptide Proteomics (MAPPs) is an ex vivo method used to assess the immunogenicity risk of biotherapeutics. MAPPs can identify potential T-cell epitopes within the biotherapeutic molecule. Using adalim
Externí odkaz:
https://doaj.org/article/0bd769f29dfe4b1888748f001e7e2a9e
Autor:
Gail Lewis Phillips, Guangmin Li, Jun Guo, Shang-Fan Yu, Genee Lee, Donglu Zhang, Peter Dragovich, Thomas Pillow, Binqing Wei, M. Violet Lee, Ola Saad, Shab Masih, Douglas Leipold, Lisa Crocker, Melissa Schutten
Publikováno v:
Cancer Research. 82:P2-13
Background: Many HER2-directed antibody-drug conjugates (ADCs) in early development employ trastuzumab linked to tubulin binding agents as the cytotoxic drug. DHES0815A is an ADC consisting of a THIOMABTM humanized IgG1 anti-HER2 monoclonal antibody
Autor:
Gail Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter Fields, Genee Lee, Donglu Zhang, Peter Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Timothy Wilson, Michael Mamounas, M Violet Lee, Ola Saad, Voleak Choeurng, Alexander Ungewickell, Shararah Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung-Hae Jung, Erika Hamilton, Patricia LoRusso, Ian Krop, Melissa Schutten, Renee Commerford, Mark Sliwkowski, Eunpi Cho, Douglas leipold
Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a novel HER2 ADC, we selected an antibody that does not compete with trastuzumab or pertuzumab for binding,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99124dcde0d6f94bd769d813e20dfcab
https://doi.org/10.21203/rs.3.rs-2322502/v1
https://doi.org/10.21203/rs.3.rs-2322502/v1
Autor:
Victor Yip, Shuguang Ma, M. Violet Lee, S. Cyrus Khojasteh, Amrita V. Kamath, Hao Cai, Nina Ljumanovic, Sylvia C. Wong, Ola Saad, Ben-Quan Shen
Publikováno v:
Drug Metabolism and Disposition. 48:1161-1168
Invasive Staphylococcus aureus infection is a leading cause of infectious disease-related deaths because S. aureus survives within host phagocytic cells, from which the bacteria are not adequately eliminated using current antibiotic treatments. Anti-
Autor:
Deborah Chasman, Yi‐Hsuan Ho, David B Berry, Corey M Nemec, Matthew E MacGilvray, James Hose, Anna E Merrill, M Violet Lee, Jessica L Will, Joshua J Coon, Aseem Z Ansari, Mark Craven, Audrey P Gasch
Publikováno v:
Molecular Systems Biology, Vol 10, Iss 11, Pp n/a-n/a (2014)
Abstract Stressed cells coordinate a multi‐faceted response spanning many levels of physiology. Yet knowledge of the complete stress‐activated regulatory network as well as design principles for signal integration remains incomplete. We developed
Externí odkaz:
https://doaj.org/article/06b8235ccb524af8a37b83247b850aa4
Publikováno v:
Journal of Clinical Medicine
Polatuzumab vedotin (or POLIVY®), an antibody–drug conjugate (ADC) composed of a polatuzumab monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable dipeptide linker, has been approved by the United States Food and Drug Ad
Autor:
Hao, Cai, Victor, Yip, M Violet, Lee, Sylvia, Wong, Ola, Saad, Shuguang, Ma, Nina, Ljumanovic, S Cyrus, Khojasteh, Amrita V, Kamath, Ben-Quan, Shen
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 48(11)
Invasive
Autor:
Melissa Schutten, Brandon Latifi, Ola Saad, Steven T Laing, Shabkhaiz Masih, Jintang He, Isabel Figueroa, Katherine R. Kozak, Douglas D. Leipold, Randall C. Dere, M. Violet Lee, Brian R. Vuillemenot, Andrew Polson, Keyang Xu, Ben-Quan Shen, Montserrat Carrasco-Triguero, Luna Liu, Dian Su, Victor Yip, Bing Zheng, Amrita V. Kamath
Publikováno v:
mAbs
Few treatment options are available for acute myeloid leukemia (AML) patients. DCLL9718A is an antibody-drug conjugate that targets C-type lectin-like molecule-1 (CLL-1). This receptor is prevalent on monocytes, neutrophils, and AML blast cells, and
Publikováno v:
Analytical Chemistry. 84:4513-4519
We modified a dual-cell linear ion trap mass spectrometer to perform infrared multiphoton dissociation (IRMPD) in the low-pressure trap of a dual-cell quadrupole linear ion trap (dual-cell QLT) and perform large-scale IRMPD analyses of complex peptid